{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:29:34Z","timestamp":1773275374861,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"45","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Pancreatic acinar cell carcinoma (PACC) is a relatively rare malignancy of the exocrine pancreas. BRCA2, a cancer susceptibility gene, has been widely studied in breast and ovarian carcinomas as mutation carriers for this gene are at a high risk for cancer development. Olaparib, an oral poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, has been approved for the treatment of ovarian cancer with any BRCA 1\/2 mutations. Herein, we report the first case of a germline BRCA2-mutated unresectable advanced PACC patient who responded well to olaparib treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 59-year-old male with a family history of cancer presented with a persistent epigastric dull pain for 3 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient was diagnosed with advanced PACC based on computed tomography (CT) scan, laparotomy, and pathology.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Exploratory laparotomy, intratumoral brachytherapy by radioiodine-125 seeds, modified FOLFIRINOX chemotherapy, and targeted therapy with olaparib were administered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient responded well to olaparib until the occurrence of severe adverse drug reactions, he died as a result of multiple organ failure with an overall survival period of 12 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>As a PARP inhibitor, olaparib has remarkable curative effect not only on breast and ovarian cancers, but also on other malignancies with BRCA mutations. Patients with advanced cancer could benefit from active targeted therapy with improvement in overall survival and quality of life.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013113","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T21:26:40Z","timestamp":1541539600000},"page":"e13113","source":"Crossref","is-referenced-by-count":22,"title":["Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib"],"prefix":"10.1097","volume":"97","author":[{"given":"Mao","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pancreatic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Mou","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengzhong","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pancreatic Surgery"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.1711460103","article-title":"Morphological study of 391 cases of exocrine pancreatic tumours with special reference to the classification of exocrine pancreatic carcinoma","volume":"146","author":"Chen","year":"1985","journal-title":"J Pathol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s11605-007-0338-1","article-title":"Acinar cell carcinoma of the pancreas: an institutional series of resected patients and review of the current literature","volume":"12","author":"Seth","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"R3-20230915","first-page":"2234","article-title":"Morphological patterns of primary nonendocrine human pancreas carcinoma","volume":"35","author":"Cubilla","year":"1975","journal-title":"Cancer Res"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.surg.2008.03.006","article-title":"672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma","volume":"144","author":"Wisnoski","year":"2008","journal-title":"Surgery"},{"key":"R5-20230915","first-page":"14846","article-title":"Clinical features and CT\/MRI findings of pancreatic acinar cell carcinoma","volume":"8","author":"Tian","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1053\/j.gastro.2009.11.062","article-title":"A pancreatic mass presented with multiple hot spots in the subcutaneous fat layer on positron emission tomography. Acinar cell carcinoma with multiple fat necrosis","volume":"139","author":"Kim","year":"2010","journal-title":"Gastroenterology"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2169\/internalmedicine.51.6536","article-title":"Huge pancreatic acinar cell carcinoma with high levels of AFP and fucosylated AFP (AFP-L3)","volume":"51","author":"Hiraoka","year":"2012","journal-title":"Intern Med"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00004728-200403000-00005","article-title":"Acinar cell carcinoma of the pancreas: clinical and computed tomography manifestations","volume":"28","author":"Chiou","year":"2004","journal-title":"J Comput Assist Tomogr"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/mpa.0b013e31804bfbd3","article-title":"Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society","volume":"35","author":"Kitagami","year":"2007","journal-title":"Pancreas"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/jcp.30.2.103","article-title":"Acinar cell neoplasms of the exocrine pancreas","volume":"30","author":"Webb","year":"1977","journal-title":"J Clin Pathol"},{"key":"R12-20230915","first-page":"511","article-title":"Clinical features of acinar cell carcinoma of the pancreas","volume":"16","author":"Sumii","year":"2001","journal-title":"J Jpn Pan Soc"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00000478-199209000-00001","article-title":"Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases","volume":"16","author":"Klimstra","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1634\/theoncologist.2011-0231","article-title":"Acinar cell carcinoma of the pancreas: new genetic and treatment insights into a rare malignancy","volume":"16","author":"Lowery","year":"2011","journal-title":"Oncologist"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1200\/JCO.2002.02.005","article-title":"Clinical characteristics and outcomes from all institutional series of acinar cell carcinoma of the pancreas and related tumors","volume":"20","author":"Holen","year":"2002","journal-title":"J Clin Oncot"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"44073","DOI":"10.18632\/oncotarget.17237","article-title":"Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer","volume":"8","author":"Yarchoan","year":"2017","journal-title":"Oncotarget"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"6339","DOI":"10.1158\/1078-0432.CCR-12-1215","article-title":"Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors","volume":"18","author":"Yachida","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.3748\/wjg.v23.i45.7945","article-title":"Pancreatic acinar cell carcinoma: a review on molecular profiling of patient tumors","volume":"23","author":"Al-Hader","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0002-9440(10)64917-6","article-title":"Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC\/beta-catenin pathway","volume":"160","author":"Abraham","year":"2002","journal-title":"Am J Pathol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/path.4310","article-title":"Whole-exome sequencing of pancreatic neoplasms with acinar differentiation","volume":"232","author":"Jiao","year":"2014","journal-title":"J Pathol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00428-014-1657-8","article-title":"Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases","volume":"465","author":"Bergmann","year":"2014","journal-title":"Virchows Arch"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-14-0617","article-title":"Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes","volume":"4","author":"Chmielecki","year":"2014","journal-title":"Cancer Discov"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1038\/srep08829","article-title":"Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas","volume":"5","author":"Furukawa","year":"2015","journal-title":"Sci Rep"},{"key":"R25-20230915","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/aja.2011.150","article-title":"The role of BRCA1 and BRCA2 in prostate cancer","volume":"14","author":"Castro","year":"2012","journal-title":"Asian J Androl"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1586\/14737140.2015.1086271","article-title":"Pancreatic cancer: BRCA mutation and personalized treatment","volume":"15","author":"Luo","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1056\/NEJMra012284","article-title":"Breast and ovarian cancer","volume":"348","author":"Wooster","year":"2003","journal-title":"N Engl J Med"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ygyno.2015.02.017","article-title":"Two decades beyond BRCA1\/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy","volume":"137","author":"Walsh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"362s17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"10254","DOI":"10.3748\/wjg.v22.i46.10254","article-title":"Response of BRCA1-mutated gallbladder cancer to olaparib: a case report","volume":"22","author":"Xie","year":"2016","journal-title":"World J Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811090-00048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T21:07:41Z","timestamp":1694812061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811090-00048"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":30,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013113","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}